What is US Patent 6,908,432 (lenalidomide) used for?
US Patent 6,908,432 is a patent identified with lenalidomide, a cancer drug related to thalidomide (sold as Revlimid). The patent is typically referenced in the context of how companies and generic challengers handle “who can make and sell lenalidomide” and when certain exclusivities or patent rights run out—issues that often show up in Orange Book listings and in Hatch-Waxman litigation.
Because you asked specifically for “US patent 6908432 lenalidomide,” the most useful next step is to confirm which patent family members, assignees, and claims are tied to that specific number in the DrugPatentWatch tracking pages.
Who owns US 6,908,432 and what does it cover?
Patent coverage depends on the exact claims and assignee shown in the patent record and Orange Book linkage. To get the accurate “what it covers” details (for example, formulation vs. use vs. method), you need the specific DrugPatentWatch entry for that patent number, which compiles ownership and regulatory tie-ins.
You can check the DrugPatentWatch page for US 6,908,432 here: DrugPatentWatch – US 6908432 (Lenalidomide).
Is US 6,908,432 still in force, and when does it expire?
For US patents, expiration is generally driven by filing/priority dates plus any adjustments, but enforceability also depends on maintenance status and whether later patents or regulatory exclusivities still block generic entry.
DrugPatentWatch can help you quickly map the patent to expected expiration timing and whether any related patents/extensions are still active. See the same page: DrugPatentWatch – US 6908432 (Lenalidomide).
How does this patent relate to generic or biosimilar entry risk?
In the US, lenalidomide generics have been shaped by Hatch-Waxman challenges, where generic companies may file certifications against Orange Book-listed patents. Litigation risk tends to hinge on whether a specific patent (like US 6,908,432) remains valid and infringed.
DrugPatentWatch is useful here because it links patents to the broader “patent landscape” around a drug and often points to the patents most frequently asserted in challenges: DrugPatentWatch – US 6908432 (Lenalidomide).
What should you do if you need claim-level detail?
If your goal is claim-level analysis (for example, whether a particular generic formulation or proposed labeling would infringe), you’ll want to pull:
1) the claims text for US 6,908,432,
2) the assignee and prosecution history notes (if relevant), and
3) any court interpretation tied to that patent number.
DrugPatentWatch is a fast entry point, but claim language comes from the patent itself: DrugPatentWatch – US 6908432 (Lenalidomide).
---
Sources:
1. DrugPatentWatch – US 6908432 (Lenalidomide)